Notch versus the proteasome: What is the target of γ-secretase inhibitor-I?

7Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

γ-Secretase inhibitors are new anti-cancer agents targeting Notch signaling. Their specificity for Notch is as yet unclear. Han and colleagues investigated the effects of Z-LeuLeuNleu-CHO on growth of breast cancer cells. The results demonstrated a reduction in cell viability primarily via proteasome inhibition independent of Notch activity. Currently, γ-secretase inhibitors in clinical trials are structurally distinct from Z-LeuLeuNleu-CHO. Their effects on the proteasome are yet to be determined. However, findings from Han and colleagues pose two critical questions: Is the level of proteasomal activity in breast tumors the driving force for growth? What does the Notch pathway contribute to this growth?© 2009 BioMed Central Ltd.

Cite

CITATION STYLE

APA

Clementz, A. G., & Osipo, C. (2009, October 15). Notch versus the proteasome: What is the target of γ-secretase inhibitor-I? Breast Cancer Research. https://doi.org/10.1186/bcr2407

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free